Get the Stockscreener App
1.37
1.79%
-0.03
After Hours:
1.36
-0.01
-0.73%
Macrogenics Inc stock is traded at $1.37, with a volume of 480.11K.
It is down -1.79% in the last 24 hours and down -20.75% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.40
Open:
$1.38
24h Volume:
480.11K
Relative Volume:
0.74
Market Cap:
$86.43M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-0.8671
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-8.94%
1M Performance:
-20.75%
6M Performance:
-61.70%
1Y Performance:
-67.57%
1-Day Range:
$1.30
$1.445
1-Week Range:
$1.30
$1.58
52-Week Range:
$0.9897
$5.77
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.37 | 99.68M | 139.77M | -97.62M | -61.71M | -1.58 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MacroGenics (NASDAQ:MGNX) Upgraded to Hold at Wall Street Zen - Defense World
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics’ SWOT analysis: biotech firm’s stock faces pipeline challenges By Investing.com - Investing.com South Africa
MacroGenics’ SWOT analysis: biotech firm’s stock faces pipeline challenges - Investing.com
Lazard Asset Management LLC Purchases New Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Northern Trust Corp Has $1.76 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Millennium Management LLC Sells 671,179 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Q2 Earnings Forecast for MacroGenics Issued By B. Riley - Defense World
MacroGenics Holds Annual Stockholders Meeting on May 21 - TipRanks
B. Riley Issues Pessimistic Forecast for MacroGenics (NASDAQ:MGNX) Stock Price - Defense World
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher - simplywall.st
4 Analysts Assess Macrogenics: What You Need To Know - Benzinga
Macrogenics (MGNX) Target Price Reduced by B. Riley Securities | MGNX Stock News - GuruFocus
MacroGenics (MGNX) Sees Target Price Cut Amid Pipeline Focus | MGNX Stock News - GuruFocus
B. Riley Cuts Price Target on MacroGenics to $3 From $5, Keeps Neutral Rating - marketscreener.com
Stifel Nicolaus Cuts MacroGenics (NASDAQ:MGNX) Price Target to $5.00 - Defense World
Stifel Financial Corp Decreases Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Leerink Partnrs Predicts Weaker Earnings for MacroGenics - Defense World
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50 - Yahoo Finance
MacroGenics Inc. Reports Q1 2025 Financial Results - TipRanks
Dimensional Fund Advisors LP Has $2.33 Million Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MGNX: Barclays Lowers Price Target for Macrogenics | MGNX Stock News - GuruFocus
Stifel cuts MacroGenics stock target to $5, maintains Hold rating By Investing.com - Investing.com Canada
MacroGenics (MGNX) Exceeds Revenue Expectations with Strong Pipe - GuruFocus
Macrogenics Inc (MGNX) Q1 2025 Earnings: EPS Loss of $0.65 Beats - GuruFocus
Macrogenics (MGNX) Receives Updated Price Target from Stifel | M - GuruFocus
MacroGenics (MGNX) Price Target Lowered by Stifel | MGNX Stock N - GuruFocus
MacroGenics (MGNX) Price Target Reduced by Barclays | MGNX Stock News - GuruFocus
MacroGenics price target lowered to $3 from $8 at Barclays - TipRanks
MacroGenics Inc earnings matched, revenue fell short of estimates By Investing.com - Investing.com India
MacroGenics: Q1 Earnings Snapshot - Huron Daily Tribune
MacroGenics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results - GlobeNewswire
MacroGenics Inc earnings matched, revenue fell short of estimates - Investing.com
Macrogenics Inc (MGNX) Q1 2025 Earnings: EPS Loss of $0.65 Beats Estimate, Revenue Soars to $13.2 Million, Surpassing Expectations - GuruFocus
MacroGenics reports Q1 EPS (65c), consensus (69c) - TipRanks
Analysts Set MacroGenics, Inc. (NASDAQ:MGNX) Target Price at $7.43 - Defense World
What To Expect From Macrogenics Inc (MGNX) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Increases Stock Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MGNX DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Class Action Filed Against MacroGenics, Inc. (MGNX)September 24, 2024 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
Barclays PLC Increases Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Levi & Korsinsky Announces an Investigation on Behalf of MacroGenics, Inc. (MGNX) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
MacroGenics, Inc. (NASDAQ:MGNX) Shares Acquired by MetLife Investment Management LLC - Defense World
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Macrogenics Inc Stock (MGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
| Eck Stephen L. | Chief Medical Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
34,319 |
| Eck Stephen L. | Chief Medical Officer |
Feb 08 '25 |
Option Exercise |
0.00 |
11,168 |
0 |
20,966 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):